Showing 1 - 1 of 1 Endometrial Cancers
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer (NRG-GY020)

Status: Enrolling

Investigator: Andrew Farach

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This phase III trial compares whether the addition of pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer coming back (recurrence) in patients with newly diagnosed stage I-II endometri ... Read more >

Live Chat Available